4//SEC Filing
Edwards Martin 4
Accession 0001415889-24-021823
CIK 0001679363other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 4:36 PM ET
Size
18.0 KB
Accession
0001415889-24-021823
Insider Transaction Report
Form 4
Edwards Martin
Director
Transactions
- Disposition to Issuer
Common Stock
2024-08-16−2,376→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2024-08-16−24,000→ 0 totalExercise: $31.00Exp: 2030-12-01→ Common Stock (24,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-08-16−9,996→ 0 totalExercise: $64.79Exp: 2031-06-16→ Common Stock (9,996 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-08-16−17,550→ 0 totalExercise: $24.49Exp: 2032-06-08→ Common Stock (17,550 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-08-16−12,535→ 0 totalExercise: $56.47Exp: 2033-05-31→ Common Stock (12,535 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-08-16−23,168→ 0 totalExercise: $30.52Exp: 2034-06-03→ Common Stock (23,168 underlying)
Footnotes (6)
- [F1]On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
- [F2](Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
- [F3]The Company Stock Option ("Option") vested as to 25% of the total shares on December 1, 2021, and 9.375% of the remaining shares vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
- [F4]Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
- [F5]The Option is fully vested.
- [F6]The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.
Documents
Issuer
Morphic Holding, Inc.
CIK 0001679363
Entity typeother
Related Parties
1- filerCIK 0001640073
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 4:36 PM ET
- Size
- 18.0 KB